Otsuka Can’t Add Huahai to Patent Suit on Teva Jynarque Generics

A federal judge rejected Otsuka Holdings Co.'s request to add a defendant in its case over Teva Pharmaceutical Industries Ltd.’s copy of the kidney disease drug Jynarque, finding the addition of the Chinese supplier risks “months of delay” that could jeopardize an October 2024 trial.

“Considering that it is pretty apparent that Otsuka’s primary purpose for joining” Zhejiang Huahai Pharmaceutical Co. is to obtain discovery from it, “there is no justification for the increased risk of prejudice,” Judge Richard G. Andrews wrote in an opinion issued Oct. 20 in the US District Court for the District of Delaware. “Huahai is ...